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Abstract
Background: Patients with hip fracture frequently have sarcopenia and are at great risk of loss of mobility. We have
investigated if sarcopenia predicts change in mobility after hip fracture.
Methods: This is a prospective, multicenter observational study with one-year follow-up. Patients with hip fracture
who were community-living and capable of walking before the fracture were included at three hospitals in Norway
(2011–2013). The primary outcome of the study was change in mobility, measured by the New Mobility Score
(NMS). Sarcopenia was determined postoperatively by anthropometry, grip strength, and NMS.
Results: We included 282 participants and sarcopenia status was determined in 201, of whom 38% (77/201) had
sarcopenia, 66% (128/194) had low muscle mass, 52% (116/222) had low grip strength and 8% (20/244) had low
pre-fracture mobility (NMS < 5). Sarcopenia did not predict change in mobility (effect 0.2 points; 95% CI –0.5 to 0.9,
P = 0.6), but it was associated with having lower mobility at one-year (NMS 5.8 (SD 2.3) vs. 6.8 (SD 2.2), P = 0.003),
becoming a resident of a nursing home (odds ratio 3.2, 95% CI 0.9 to 12.4, P = 0.048), and the combined endpoint
of becoming a resident of a skilled nursing home or death (odds ratio 3.6, 95% CI 1.2 to 12.2, P = 0.02).
Conclusions: Sarcopenia did not predict change in mobility in the year after hip fracture.
Keywords: Activities of daily living, Hip fractures, Independent living, Mobility limitation, Skilled nursing facilities,
Sarcopenia
Background
A hip fracture is associated with severe and persisting mo-
bility impairment in more than half of patients [1]. For the
last 30 years, a substantial effort has been made to under-
stand the condition of sarcopenia, and several definitions
have been proposed [2]. Sarcopenia has recently been rec-
ognized as an independent condition with its own ICD-10
code [3]. One of the most widely used definitions is by the
European Working Group on Sarcopenia in Older Persons
(EWGSOP): low muscle mass with low muscle strength or
low physical performance [4]. Previous studies on sarcope-
nia in patients with hip fracture have been cross-sectional,
single-center, have included few participants or have had
short follow-ups [5–10]. The three components of EWG-
SOP sarcopenia have different associations with mobility
after hip fracture. Physical performance and mobility are
strong determinants of mobility after hip fracture [11, 12].
Muscle strength is a somewhat weaker predictor [13, 14],
whereas the studies on muscle mass have been inconclusive
[15]. Our primary hypothesis is that sarcopenia, determined
by methods suitable for bed-side use, predicts change in
mobility in the year after hip fracture and therefore that sar-
copenia status is useful for determining prognosis and is a
possible cause of mobility impairment. Further, we aim to
describe the associations of sarcopenia and the individual
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components of sarcopenia (muscle mass, grip strength and
mobility) and adverse clinical outcomes in the year after
hip fracture: change in activities of daily living, reoperations
for hip fracture, all-cause hospitalization, fractures, becom-
ing a resident of a nursing home or death.
Methods
Study design
We conducted a prospective observational study of sar-
copenia in patients with acute hip fracture with follow-
up at three months and one year, conducted at three
Norwegian hospitals in 2011–2013.
Participants
Participants were included while in hospital in the postop-
erative phase. Eligible participants were aged ≥65 years,
able to give informed consent as judged by experienced
clinicians, were living in the community, and were ambu-
latory before the fracture. Patients who were unstable such
as with delirium, acute respiratory failure or in severe pain
were not eligible. Other exclusion criteria were dementia
when it made informed consent impossible, remaining life
expectancy of less than three months and bone disease
other than osteoporosis or osteomalacia. We screened for
participants by examining lists of patients admitted for hip
fracture or staying on the hospital wards.
Data collection
Information was collected by the authors and study
personnel by examination, chart review, routine blood
tests and by interviews with patients and their caregivers
from the first postoperative day and until discharge from
hospital. Weight was measured with the scales on the
hospital wards. We collected the American Society of
Anesthesiologists (ASA) score, Charlson comorbidity
index [16], Barthel activities of daily living (B-ADL)
score [17], length of the acute care hospital stay, previ-
ous hip fracture and type of hip fracture. Follow-up was
at 3 months at an outpatient clinic and at one year as a
telephone interview with the patient or care-giver. Infor-
mation on previous and subsequent hip fractures, and
reoperations for the index hip fracture came from the
Norwegian Hip Fracture Register [18]. This register
started data collection in 2005 and has coverage on an
estimated 90% of all hip fractures in Norway. The regis-
ter has information on reoperations, with an estimated
coverage of 65% of hip fractures treated with surgical
pinning, 68% after hemiarthroplasty and 93% after total
hip replacement [19]. Mortality data was supplied by the
National Population Register, which is complete.
Sarcopenia
Participants were classified as sarcopenic if they had low
muscle mass and either low grip strength or impaired
mobility, as described by the EWGSOP [4]. Total body
muscle mass was determined by anthropometry by the
method of Heymsfield et al. using height, arm circumfer-
ence and triceps skinfold [20]. Arm circumference was
measured on the right arm using a non-elastic tape at
the mid-point of the acromion and olecranon process,
and triceps skinfold was measured on the posterior as-
pect of the same arm at the same level using a skinfold
caliper (Harpenden, Baty International, Great Britain).
Height was measured by a wall mounted stadiometer, or
if the patients was unable to stand self-reported height
was used. If the participant was unable to stand or re-
port their height, the length from heel to crown was
measured while lying in bed. In cases with missing value
on height at baseline, height measured at follow-up was
used. The values for total body muscle mass were trans-
formed to appendicular lean mass (ALM) using model 1
described by Kim et al. [21]. The cut-points for low
muscle mass were ALM ≤7.25 kg/m2 for men and
≤5.67 kg/m2 for women. We chose anthropometry for
its ease of use at the bed-side in immobile hip fracture
patients. Grip strength was measured with a Jamar Hy-
draulic Dynamometer (Sammons Preston, USA) while
the patient was sitting in bed or on a chair with the
elbow flexed, the wrist in the neutral position and with
verbal encouragement. Grip strength was measured
three times on each hand with short intervals between
each attempt while the grip was repositioned. The single
best value out of these six measurements was used. Low
grip strength was ≤30 kg for men and ≤20 kg for
women. Mobility in the two weeks before the hip frac-
ture was determined by interview using the New Mobil-
ity Score (NMS). The NMS is scored 0–9 according to a
person’s ability to walk indoors, outdoors, or while shop-
ping [22]. The cut-point for low mobility was chosen as
< 5, as this has been used to predict mortality after hip
fracture [23]. We used a Danish version of the NMS
with minimal modifications to Norwegian. Sarcopenia
status was determined postoperatively and at follow-up.
Outcome measures
The primary outcome was change in mobility, calculated
as NMS at one year minus the pre-fracture NMS. We
believe that change in mobility is more relevant than
mobility for identifying patients who are more likely to
benefit from interventions. We determined mobility pre-
fracture, at three months, and at one-year. All other ana-
lyses were considered exploratory. Other outcome vari-
ables at one year were NMS at one year, B-ADL at one
year, change in B-ADL, new clinical fractures, new hip
fractures, reoperation for hip fracture, all-cause hospital-
izations, death, becoming a permanent resident of a
skilled nursing home, and the combined endpoint of be-
coming a permanent resident of a nursing home or
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death. The combined endpoint was chosen because
death and becoming a resident of a nursing home are
competing risks. New clinical fracture was any symp-
tomatic skeletal fracture reported by the patient.
Statistical analysis
We report descriptive data as means with standard devia-
tions or as counts with percentages. To examine the pre-
dictive effect of sarcopenia status on changes in mobility
and level of activity of daily living, we used linear regression
analyses with NMS and B-ADL as response variables and
sarcopenia status at baseline (sarcopenic vs. not sarcopenic)
and age, sex and BMI as predictors. Age, sex and BMI were
included in the models because they are established predic-
tors of mobility after hip fracture [24] or sarcopenia [25].
The relationship with age and BMI was not assumed to be
linear and was modelled using restricted cubic splines with
3 knots, placed at the 10%, 50% and 90% quantiles. We as-
sumed that a one-point change in NMS would be clinically
significant. We used Fisher’s exact test for the analysis of
sarcopenia associated with new clinical fracture, new hip
fracture, reoperations, all-cause hospitalization, becoming a
resident of skilled nursing home, and the combined end-
point of nursing home or death. The association between
the separate components of sarcopenia (muscle mass, grip
strength and mobility) with change in mobility, change in
B-ADL and the combined endpoint of becoming a resident
of a skilled nursing home or death was analysed using re-
gression analysis. Muscle mass, grip strength and mobility
were independent continuous variables, and were analyzed
separately. Change in mobility and change in B-ADL were
continuous, dependent variables and the combined end-
point of becoming resident of a nursing home or death was
a dichotomous dependent variable.
For the regression analyses, we used multiple imput-
ation (500 imputations), based on predictive mean match-
ing, using the ‘aregImpute()’ function in the ‘rms’ R
package [26]. The variables used in the imputation models
were the ones included in the regression models, variables
highly correlated with these variables and variables ex-
pected to explain the missing data mechanism: NMS at
baseline, follow-up, and at one year, and change in NMS
from baseline to one year, B-ADL before the hip fracture
and change in B-ADL from pre-fracture until one year,
sarcopenia status at baseline, BMI at baseline, ASA score
during hip fracture surgery, previous hip fracture, serum
albumin when in hospital, grip strength at follow-up, sex,
clinical fractures and hip fractures in the year after admis-
sion, becoming a resident of a skilled nursing home, or
dying in the following year. All continuous predictors
were modelled linearly in the imputation model. The im-
putation analyses were done in R 3.3.0 [27] and the rest of
the analyses were done in Stata 14 (Stata Corp., USA). P-
values ≤0.05 were considered significant.
Results
All patients in hospital with confirmed hip fracture were
considered for inclusion if the research staffs at the different
hospitals were present. Some patients were unable to partici-
pate because they were discharged before the two-day con-
sent process was completed. There was no systematic
recording of the patients who were screened, but not in-
cluded. Figure 1 describes the progress of participants
through hip fracture, inclusion in the study and follow-up.
During the period of inclusion 1592 patients had surgery for
hip fracture and 282 patients were included in the study.
Mean age was 79.4 (SD 8.2) years and 76% were female.
Mean BMI was 24.1 (SD 4.3) kg/m2, with a wide range 13.0
to 44.7 kg/m 2. See Table 1 for baseline demographics. One
patient died during the hospital stay. Participants who had
missing data on sarcopenia status during hospitalization
had lower pre-fracture NMS and pre-fracture B-ADL and
were more likely to become a permanent resident of a
skilled nursing home. For 69 participants, height was not
assessed during the hospital stay, and for 52 of these, height
determined at follow-up was used.
Sarcopenia
Sarcopenia status during hospitalization for hip fracture
was determined in 201 participants, and 39% (77/201)
had sarcopenia. Low muscle mass was present in 66%
(128/194) of the participants, low grip strength in 52%
(116/222), and 8% had low pre-fracture mobility (19/
243). One participant did not have muscle mass deter-
mined but had grip strength and NMS above the cut-
points and was considered not-sarcopenic. Figure 2.
Participants with sarcopenia were older, had lower BMI,
greater ASA score at operation, greater prevalence of
previous hip fracture and pulmonary disease and lower
B-ADL before the fracture. Grip strength and ALM were
assessed at a median of 4 days after surgery (interquar-
tile range 3 to 6 days) (Fig. 2).
Outcomes after one year
Sarcopenia was not associated with change in mobility
at one year in unadjusted or adjusted analyses (e.g., the
change in NMS was an additional 0.2 in sarcopenic pa-
tients compared to non-sarcopenic patients, 95% CI: –
0.5 to 0.9, P = 0.6); see Table 2 for outcomes at one-year.
Sarcopenia status at hospitalization did not predict
change in mobility from pre-fracture to 3 months, or
from 3 months to one-year. Results were not affected by
imputation of missing values. Mobility was reduced in
54% of participants one year after hip fracture, with a
mean NMS of 6.4 (SD 2.2). See Fig. 3 for NMS by sarco-
penia status during the year after hip fracture. Figure 4
describes the relationship between specific scores on the
NMS pre-fracture and at one-year. Participants with sar-
copenia had lower mobility at one-year, NMS 5.8 (SD
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2.3) vs. 6.8 (SD 2.2), P = 0.003, and greater impairment
in B-ADL, 16.8 (SD 4.4) vs. 18.6 (SD 2.8), P = 0.001,
compared to patients without sarcopenia. Sarcopenia
was associated with becoming a permanent resident of a
skilled nursing home (OR 3.2, 95% CI: 0.9 to 12.4, P =
0.048) and the combined endpoint of becoming a resi-
dent of a skilled nursing home or death (OR 3.6, 95%
CI: 1.2 to 12.3, P = 0.02).
Muscle mass, grip strength and mobility
Muscle mass or grip strength was not associated with
any outcome in adjusted analysis Table 3. In unadjusted
analysis, grip strength and NMS were associated with a
reduced risk of becoming a resident of a nursing home
or death. The NMS was positively associated with
change in B-ADL in adjusted analysis (estimate 0.2 per
point, 95% CI 0.0 to 0.4, P = 0.03).
Discussion
The aim of this study was to investigate if sarcopenia
predicted change in mobility after hip fracture. We
found that sarcopenia status did not predict change in
mobility in unadjusted analysis, which indicates that
sarcopenia is not useful in determining prognosis. Fur-
ther, sarcopenia did not predict change in mobility in
analysis adjusted for age, sex and BMI, which indicates
that sarcopenia status is not likely to be causally related
to developing reduced mobility. We used multiple im-
putation to reduce the loss of information associated
with missing values. This approach is considered inferior
to having all the data, but preferable to performing ana-
lysis on complete data. One assumption of multiple im-
putation is that missing values can be estimated by the
remaining information in the dataset. The results of our
analysis were similar when analyzing complete cases and
when analyzing datasets with imputed values, indicating
that the results of our analysis are valid even if this as-
sumption was erroneous.
Change in mobility was not associated with sarcopenia
and this was consistent across all the investigated time
periods, from baseline to three months, from baseline to
one year and from three months to one year. Mobility
from before the hip fracture until one year is character-
ized by an initial loss of mobility and a subsequent par-
tial recovery. Sarcopenia is not associated with either the
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n = 120
Follow-up by
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Fig. 1 Overview of patients with hip fracture, patients included in the study and patients returning for follow-up
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that sarcopenia is not related to change in mobility. In
contrast to change in mobility, being sarcopenic was as-
sociated with having lower mobility pre-fracture, at three
months and at one year, compared to not being sarcope-
nic. This is expected, since low mobility is one criteria
for sarcopenia. As seen in Fig. 4, pre-fracture mobility is
a determinant of mobility at three months and one year.
Savino et al. found that grip strength measured in hos-
pital predicted recovery of walking ability in patients
with hip fracture [13]. In contrast, our findings indicate
that neither muscle mass nor grip strength, when ana-
lysed as continuous variables, were associated with
change in mobility. This indicates that the choice of cut-
points for low muscle mass or low grip strength would
not have changed our results. We found an association
between mobility pre-fracture and change in activities in
daily living, but this was an exploratory analysis and the
effect size was small.
Sarcopenia was associated with an increased probability
of becoming a resident of a skilled nursing home (OR 3.2,
95% CI 0.9 to 12.4, P = 0.048) and the combined endpoint
of becoming a resident of a nursing home or death (OR
3.6, 95% CI 1.2 to 12.3, P = 0.02). This is a clinically relevant
finding but must be interpreted with caution, as it was an
exploratory outcome and we were not able to correct for
age, sex or BMI because of the low number of outcomes.
Among the participants who had sarcopenia status deter-
mined, 6 participants died or became permanent residents
of a nursing home among the not sarcopenic and 12 partic-
ipants among those who were sarcopenic. The NMS was
chosen as our measure of physical performance because we
assumed that many participants would be unable to walk at
inclusion. The NMS is extensively studied as a predictor of
mobility, morbidity, mortality and becoming a resident of a
nursing home [28–31]. We found a ceiling effect with the
NMS, with 54% of participants scoring the maximum 9 be-
fore the fracture and 30% at one-year. Possibly because par-
ticipants with a pre-fracture NMS of 0 or 1 were not
eligible for inclusion. Patients found the NMS easy to
understand and scoring was straightforward. Surprisingly,
we found that 8% of patients had better mobility at one-
year compared to pre-fracture. For some of the patients this
was due to illness that started before the fracture, and their
improvement in mobility after hip fracture was due to reso-
lution of their illness, rather than successful rehabilitation.
Use of rehabilitation services improves mobility after hip
fracture [32, 33]. We did not record what rehabilitation ser-
vices the participants received, and it is possible that re-
habilitation could mediate the effect between sarcopenia
and change in mobility.
The participants in our study were slightly younger (79.4
vs. 80.0 years) and had a lower mean ASA score (2.5 vs. 2.7)
indicating better health compared to patients in the
Norwegian Hip Fracture Register. We did not include
Table 1 Baseline characteristics of participants by sarcopenia status
Not sarcopenic Sarcopenic P-value
Age, years (SD) 77.1 (7.8) n = 124 81.8 (7.6) n = 77 < 0.0001
Female, n (%) 95 (77) n = 124 56 (72) n = 77 0.5
Barthel ADL
pre-fracture (SD)
19.5 (1.1) n = 85 18.7 (1.9) n = 60 0.006




29 (24) n = 123 14 (18) n = 77
Neck of femur,
displaced, n (%)
46 (37) n = 123 31 (40) n = 77
Trochanteric,
n (%)
48 (39) n = 123 32 (42) n = 77
ASA score (SD) 2.3 (0.6) n = 124 2.7 (0.6) n = 77 < 0.001
Previous hip
fracture, n (%)
5 (4) n = 124 9 (12) n = 77 0.039
Charlson score (SD) 0.9 (1.3) n = 124 1.1 (1.3) n = 77 0.15
Heart failure, n (%) 7 (6) n = 124 6 (8) n = 77 0.5
Previous myocardial
infarction, n (%)
14 (11) n = 124 9 (12) n = 77 0.9
Cerebrovascular
disease, n (%)
13 (10) n = 124 8 (10) n = 77 0.98
Diabetes
mellitus, n (%)
9 (7) n = 124 10 (13) n = 77 0.2
Any solid
tumor, n (%)
7 (6) n = 124 8 (10) n = 77 0.2
Pulmonary
disease, n (%)
15 (12) n = 124 18 (23) n = 77 0.036
Length of hospital
stay, days (SD)
6.8 (2.7) n = 124 9.6 (6.7) n = 77 < 0.001
Body composition
BMI, kg/m2 (SD) 25.6 (4.2) n = 107 22.1 (3.7) n = 70 < 0.001
ALM/height2,
kg/m2 (SD)
6.3 (1.5) n = 111 4.4 (1.0) n = 77 < 0.001
Women 6.1 (1.3) n = 86 4.3 (0.8) n = 56 < 0.001




27.0 (10.3) n = 123 16.5 (6.4) n = 77 < 0.001
Women 22.9 (6.9) n = 94 14.3 (5.0) n = 56 < 0.001




8.0 (1.5) n = 123 7.1 (2.0) n = 74 < 0.001
Women 8.0 (1.6) n = 94 7.1 (2.0) n = 55 0.008
Men 8.2 (1.4) n = 29 6.8 (2.2) n = 19 0.017
Baseline characteristics by sarcopenia status (means with standard deviations
and counts with percentages). P-values for comparison of groups are by the
Mann–Whitney–Wilcoxon test, except for type of fracture which is by
chi-squared test. Trochanteric fractures include basocervical femoral neck
fractures and subtrochanteric fractures. Previous hip fracture indicates a
previous hip fracture, either left or right hip. ALM: Appendicular lean mass,
ADL: Activities of daily living
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patients from skilled nursing homes or with severe cognitive
impairment, and our results are not generalizable to those
populations.
Anthropometry is considered a less valid method for
determining muscle mass compared to dual-energy X-
ray absorptiometry (DXA) or computed tomography
scan [34]. The EWGSOP recommends not using anthro-
pometry to determine muscle mass in research but al-
lows for it in clinical practice [4]. We have previously
investigated how anthropometry compares to DXA in
identifying low muscle mass and found an area under
the curve of 0.64 (95% CI 0.54–0.75) in women and 0.72
(95% CI 0.56–0.87) in men [35]. Using anthropometry to
identify low muscle mass instead of DXA can lead to
misclassification of muscle mass status and hence sarco-
penia status. By using anthropometry to determine sar-
copenia status we reduced our ability to detect an effect
of sarcopenia on outcomes. We used anthropometry in
our study because it is in common use [36], inexpensive,
and more easily performed on patients with reduced
mobility and acute illness, compared to DXA [37]. Some
consider objectively measured physical performance su-
perior to self-reported mobility, such as the NMS, but
when the two types of measurement are compared in
Fig. 2 What participants were assessed for muscle mass, grip strength, mobility and sarcopenia
Table 2 Outcomes after one year by sarcopenia status
Marginal values Regression (sarcopenic – not sarcopenic)
Not sarcopenic Sarcopenic Unadjusted Adjusted
Mean (SD) No. Mean (SD) No. Estimate 95% CI P Estimate 95% CI P
Change NMS −1.2 (1.8) n = 117 −1.3 (1.9) n = 67 0.0 −0.6 to 0.6 0.9 0.2 −0.5 to 0.9 0.6
Change B-ADL −0.8 (2.4) n = 76 −2.2 (3.9) n = 52 −0.4 −1.2 to 0.3 0.3 −0.3 − 1.1 to 0.6 0.6
Not Sarcopenic Sarcopenic OR 95% CI P
Fracture, n (%) N 7 (6) n = 120 8 (11) n = 71 2.0 (0.6 to 7.0) 0.3
Hip fractures, n (%) N 3 (2) n = 124 3 (4) n = 77 1.6 (0.2 to 12.5) 0.7
Reoperations, n (%) N 7 (6) n = 124 1 (1) n = 77 0.2 (0.0 to 1.8) 0.2
Hospitalization, n (%) N 41 (33) n = 123 24 (33) n = 73 1.0 (0.5 to 1.9) 1.0
Nursing home, n (%) N 5 (4) n = 124 9 (12) n = 77 3.2 (0.9 to 12.4) 0.048
Death, n (%) N 3 (2) n = 124 5 (6) n = 77 2.8 (0.5 to 18.5) 0.3
Death or nursing home, n (%) N 6 (5) n = 124 12 (16) n = 77 3.6 (1.2 to 12.3) 0.02
Outcomes after one year by sarcopenia status (sarcopenic – not sarcopenic). Regression analysis for change in mobility and Barthel ADL from pre-fracture until
one year adjusted for age, sex and BMI with imputation of missing values. ADL: Barthel Activities of daily living. Analysis for fracture, hip fracture, reoperations,
all-cause hospitalization, nursing home, death or nursing home or death by two-sided Fisher’s exact test using available cases. NMS: New mobility score. B-ADL:
Barthel activities of daily living. OR: Odds ratio
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Fig. 3 New Mobility Score (NMS) during hospitalization, at three months, and at one year, stratified by sarcopenia status during hospitalization.
The horizontal lines show mean NMS scores
Fig. 4 New Mobility Score (NMS) pre-fracture and at one-year follow-up. The first number in each cell is the number of patients with the given
combination of NMS scores. For each row, the percentage values and the cell shadings show the distribution of NMS at follow-up for a given
NMS score at baseline. No patients had a NMS of 1 at baseline, and patients with a NMS score of 0 was excluded from the study. Patients with
the same NMS score at baseline and follow-up are shown in boldface, and any cell to the right of this diagonal indicates an improvement in
the NMS
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hip fracture patients they have been found to be equally
predictive of outcomes [38]. Future research on sarcope-
nia in hip fracture patients could explore other methods
for determining sarcopenia, such as computed tomog-
raphy to directly measure intramuscular adipose tissue
[34] or using objective measures of physical performance
such as the Short Physical Performance Battery [39]. A
randomized controlled study of an intervention targeting
sarcopenia status to improve mobility after hip fracture
would provide additional insight on the causal relation
between sarcopenia and mobility.
The included patients were a minority of all patients
operated on for hip fracture during the period of
inclusion. We included postoperative patients who were
frequently bed-bound, receiving opiates for pain relief,
with indwelling urinary catheters and while receiving
intravenous fluid therapy. We believe there were three
main reasons for the low recruitment rate: patients did
not fulfill the inclusion criteria, patients were discharged
before the consent process could be completed, and
participants declined to participate because it was too
much of a burden. For the patients who did consent to
participate we found that determining sarcopenia by
anthropometry, grip strength and the NMS was feasible.
The greatest difficulty was in determining the height of
the participants.
Conclusion
Sarcopenia status determined in postoperative hip frac-
ture patients by anthropometry, grip strength and self-
reported mobility did not predict change in mobility in
the year after hip fracture. Sarcopenia was associated
with having lower mobility at one year and a greater risk
of becoming a resident of a nursing home or death.
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sør-øst B) and was conducted according to the principles of the Declaration
of Helsinki. Participation was by written informed consent with participants
receiving oral and written information on the first day and signed the
consent form on a subsequent day.
Consent for publication
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Table 3 Outcomes after one year predicted by muscle mass, grip strength or mobility
Unadjusted
β (95% Confidence interval)
Adjusted
β (95% Confidence interval)
Change in New Mobility Score at one year
ALM/height2, kg/m2 0.0 (−0.1 to 0.2) p = 0.7 n = 175 0.2 (−0.1 to 0.4) p = 0.2 n = 155
Grip strength, kg 0.0 (−0.0 to 0.0) p = 0.7 n = 193 −0.0 (−0.0 to 0.0) p = 0.7 n = 169
Change in Barthel activities of daily living at one year
ALM/height2, kg/m2 0.0 (−0.2 to 0.3) p = 0.8 n = 121 0.1 (−0.2 to 0.4) p = 0.4 n = 115
Grip strength, kg 0.0 (−0.0 to 0.1) p = 0.07 n = 137 0.0 (0.0 to 0.1) p = 0.1 n = 128
New Mobility Score, point 0.2 (0.0 to 0.4) p = 0.03 n = 148 0.2 (0.0 to 0.4) p = 0.03 n = 130
Death or nursing home at one year
ALM/height2, kg/m2 0.8 (0.6 to 1.2) p = 0.3 n = 194 1.0 (0.6 to 1.7) p = 1.0 n = 170
Grip strength, kg 0.9 (0.9 to 1.0) p = 0.002 n = 222 0.9 (0.9 to 1.0) p = 0.1 n = 186
New Mobility Score, point 0.7 (0.6 to 0.9) p < 0.001 n = 243 0.8 (0.6 to 1.0) p = 0.06 n = 194
Outcomes after one year by muscle mass, grip strength or mobility. Analysis of change in mobility and Barthel activities of daily living by regression and with
imputation of missing values. ALM/height2, grip strength and New Mobility Score are continuous, independent variables. Change in New Mobility Score and
Barthel activities of daily living are continuous dependent variables. n: number of cases without missing values. OR: Odds ratio, ALM: Appendicular lean mass.
Adjusted analysis with age, sex and BMI as covariates
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